Receives Breakthrough Therapy Designation from US FDA for Hemophilia A Without Factor VIII Inhibitors

Receives Breakthrough Therapy Designation from US FDA for Hemophilia A Without Factor VIII Inhibitors  Business Wire (press release)Full coverage